• Completed Phase 1 diabetic foot ulcer trial with positive efficacy data
• Progressing Phase 2 aGvHD, Phase 3 osteoarthritis, and Phase 1/2 kidney transplant trials
• Remains well-capitalized with funding runway through mid-2026

Cynata Therapeutics Limited reported its financial results for the year ended 30 June 2025. The company incurred a net loss of $9,390,586 and had a cash balance of $5,049,744 and net assets of $5,981,735 at the end of the period. The company made significant progress across its clinical pipeline, completing a Phase 1 trial in diabetic foot ulcers with positive efficacy data, advancing a Phase 2 trial in acute graft versus host disease (aGvHD) to ~85% enrollment, nearing completion of a fully enrolled 321-patient Phase 3 trial in osteoarthritis, and completing treatment in the first cohort of a Phase 1/2 kidney transplant trial. Cynata remains well-capitalized with a funding runway through mid-2026 to cover these key clinical readouts. The company also advanced its preclinical programs, generating positive results in models of pulmonary fibrosis and ischemic heart disease.

Cynata expects to report results from the Phase 1/2 kidney transplant trial in Q4 2025, the Phase 2 aGvHD trial in H1 2026, and the Phase 3 osteoarthritis trial between February and April 2026.

Cynata is in a phase of significant momentum, with multiple late-stage clinical trials progressing towards important readouts in the next 12-18 months. These milestones have the potential to represent inflection points for the company's valuation, partnering, and product approval pathways.